Justify failed drug test before
Triple Crown win: New York Times
Send a link to a friend
[September 12, 2019]
(Reuters) - Champion racehorse
Justify failed a drug test shortly before winning the American
Triple Crown in 2018, the New York Times reported on Wednesday.
In an article posted on its website, the newspaper said Justify, who
was under the stewardship of Hall of Fame trainer Bob Baffert,
tested positive to the banned substance scopolamine after winning
the Santa Anita Derby on April 7.
Scopolamine, also known as hyoscine, is banned in horse racing
because it can improve horses' breathing and heart-rate.
The report said the failed drug test would normally have meant
Justify's disqualification and forfeiture of entry into the Kentucky
Derby.
Instead, the California Horse Racing Board took more than a month to
confirm the results and moved to drop the case while lightening the
penalty for any horse found to test positive to the same substance,
the report said.
Justify won the Kentucky Derby, the first leg of the Triple Crown on
May 5, before adding the Preakness Stakes and Belmont Stakes to
become the 13th horse to complete the treble.
The Times quoted California Horse Racing Board executive Rick
Baedeker as saying that it would have been "careless and reckless"
for regulators to have rushed to complete an investigative report
before the Kentucky Derby.
[to top of second column] |
Jockey Mike Smith smiles as he rides Justify across the finish line
to win the 150th running of the Belmont Stakes, the third leg of the
Triple Crown of Thoroughbred Racing at Belmont Park in Elmont, New
York, U.S., June 9, 2018. REUTERS/Lucas Jackson
Baedeker did not immediately respond to a phone call and email
request for comment by Reuters.
Efforts to contact Baffert were also unsuccessful.
(Reporting by Andrew Both in Cary, North Carolina; Editing by Ian
Ransom)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |